Table 1. Clinical and pathological characteristics of the HCA and HCC cohorts.
| HCA (n = 11) |
HCC (n = 10) |
|
|---|---|---|
| Clinical characteristics | ||
| Age | 40 (24–56) | 73 (63–81) |
| Female | 10 (91%) | 4 (40%) |
| Oral contraceptives use | 7 (64%) | — |
| Body mass index, kg/m2 | 26 (22–36) | 29 (22–33) |
| Metabolic syndrome | 4 (36%) | 6 (60%) |
| Viral hepatitis | 0 (0%) | 0 (0%) |
| Child-Pugh score | — | 5 (5–5) |
| MELD score | — | 9 (6–12) |
| AFP, ng/ml | 2 (1.3–6.3) | 15 (1.9–92881) |
| Pathological characteristics | ||
| Multiple nodules or satellites | 5 (45%) | 2 (20%) |
| Largest tumor size, cm | 5.35 (2.4–11.5) | 9.2 (3.2–17) |
| Differentiation | ||
| - Well | — | (10%) |
| - Moderate | — | (80%) |
| - Poor | — | 1 (10%) |
| Microvascular invasion | — | 5 (50%) |
| Liver fibrosis | 1 (9%) | 4 (40%) |
| Cirrhosis | 0 (0%) | 0 (0%) |
| Liver steatosis | 3 (27%) | 3 (30%) |
| Microscopic negative margin | — | 10 (100%) |
| Extracapsular extension | — | 1 (10%) |
| HCA subtypes | ||
| - Inflammatory HCA | (54%) | — |
| - Steatotic HCA | (37%) | — |
| - β-catenin HCA | 1 (9%) | 0 (0%) |
HCA, hepatocellular adenoma; HCC, hepatocellular carcinoma; MELD, Model for End-Stage Liver Disease; AFP, alpha-fetoprotein. Categorical variables are expressed as frequency (%). Continuous variables are expressed as median (range).